Roberta Palorini

Dr. Roberta Palorini


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2018 in Cells
Verified
Journal Article
Open access
PDF file
FCFerdinando Chiaradonna
Ferdinando Chiaradonna
FRFrancesca Ricciardiello
Francesca Ricciardiello
RPRoberta Palorini
Roberta Palorini
Alterations in glucose and glutamine utilizing pathways and in fatty acid metabolism are currently considered the most significant and prevalent metabolic changes observed in almost all types of tumors. Glucose, glutamine and fatty acids are the substrates for the hexosamine biosynthetic pathway (HBP). This metabolic pathway generates the “sensing molecule” UDP-N-Acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is the substrate for the enzymes involved in protein N- and O-glycosylation, two important post-translational modifications (PTMs) identified in several proteins localized in the extracellular space, on the cell membrane and in the cytoplasm, nucleus and mitochondria. Since protein glycosylation controls several key aspects of cell physiology, aberrant protein glycosylation has been associated with different human diseases, including cancer. Here we review recent evidence indicating the tight association between the HBP flux and cell metabolism, with particular emphasis on the post-transcriptional and transcriptional mechanisms regulated by the HBP that may cause the metabolic rewiring observed in cancer. We describe the implications of both protein O- and N-glycosylation in cancer cell metabolism and bioenergetics; focusing our attention on the effect of these PTMs on nutrient transport and on the transcriptional regulation and function of cancer-specific metabolic pathways.

26 September 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
FBFederica Bellerba
Federica Bellerba
VMValeria Muzio
Valeria Muzio
PGPatrizia Gnagnarella
Patrizia Gnagnarella
FFFederica Facciotti
Federica Facciotti
SCSusanna Chiocca
Susanna Chiocca
Sara GandiniSara Gandini
Sara Gandini
Recent evidence has shown a number of extra-skeletal functions of Vitamin D (VD), primarily involving the immune system. One of these functions is mediated by the modulation of gut microbiota, whose alterations are linked to many diseases. Our purpose is to contribute to the understanding of existing evidence on the association between VD and gastrointestinal microbiota alterations. A systematic review of studies with human subjects has been conducted up to January 2021. We included publications reporting the association between gut microbiota and VD, including VD supplementation, dietary VD intake and/or level of 25(OH)D. We identified 25 studies: 14 were interventional and 11, observational. VD supplementation was found to be associated with a significant change in microbiome composition, in particular of Firmicutes, Actinobacteria and Bacteroidetes phyla. Furthermore, Firmicutes were found to be correlated with serum VD. Concerning alpha and beta diversity, a high nutritional intake of VD seems to induce a shift in bacterial composition and/or affects the species’ richness. Veillonellaceae and Oscillospiraceae families, in the Firmicutes phylum, more frequently decreased with both increasing levels of 25(OH)D and vitamin D supplementation. We found evidence of an association, even though the studies are substantially heterogeneous and have some limitations, resulting sometimes in conflicting results. To further understand the role of VD on the modulation of the gastrointestinal microbiota, future research should be geared toward well-designed animal-based studies or larger randomized controlled trials (RCTs).

21 September 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
PGPatrizia Gnagnarella
Patrizia Gnagnarella
VMValeria Muzio
Valeria Muzio
Saverio CainiSaverio Caini
Saverio Caini
SRSara Raimondi
Sara Raimondi
CMChiara Martinoli
Chiara Martinoli
Sara GandiniSara Gandini
Sara Gandini
Several studies have investigated the beneficial effects of vitamin D on survival of cancer patients. Overall evidence has been accumulating with contrasting results. This paper aims at narratively reviewing the existing articles examining the link between vitamin D supplementation and cancer mortality. We performed two distinct searches to identify observational (ObS) studies and randomized clinical trials (RCTs) of vitamin D supplementation (VDS) in cancer patients and cohorts of general population, which included cancer mortality as an outcome. Published reports were gathered until March 2021. We identified 25 papers published between 2003 and 2020, including n. 8 RCTs on cancer patients, n. 8 population RCTs and n. 9 ObS studies. There was some evidence that the use of VDS in cancer patients could improve cancer survival, but no significant effect was found in population RCTs. Some ObS studies reported evidence that VDS was associated with a longer survival among cancer patients, and only one study found an opposite effect. The findings do not allow conclusive answers. VDS may have the potential as treatment to improve survival in cancer patients, but further investigations are warranted. We strongly support investment in well-designed and sufficiently powered RCTs to fully evaluate this association.

15 December 2016 in Metabolic Engineering
Verified
Journal Article
Open access
YNYannic Nonnenmacher
Yannic Nonnenmacher
RPRoberta Palorini
Roberta Palorini
ADAymeric Fouquier D'Herouël
Aymeric Fouquier D'Herouël
LKLisa Krämer
Lisa Krämer
MNMeina Neumann-Schaal
Meina Neumann-Schaal
KHKarsten Hiller
Karsten Hiller
To date, it is well-established that mitochondrial dysfunction does not only play a vital role in cancer but also in other pathological conditions such as neurodegenerative diseases and inflammation. An important tool for the analysis of cellular metabolism is the application of stable isotope labeled substrates, which allow for the tracing of atoms throughout metabolic networks. While such analyses yield very detailed information about intracellular fluxes, the determination of compartment specific fluxes is far more challenging. Most approaches for the deconvolution of compartmented metabolism use computational models whereas experimental methods are rare. Here, we developed an experimental setup based on selective permeabilization of the cytosolic membrane that allows for the administration of stable isotope labeled substrates directly to mitochondria. We demonstrate how this approach can be used to infer metabolic changes in mitochondria induced by either chemical or genetic perturbations and give an outlook on its potential applications.

18 February 2021 in Cells
Verified
Journal Article
Open access
PDF file
FRFrancesca Ricciardiello
Francesca Ricciardiello
LBLaura Bergamaschi
Laura Bergamaschi
HVHumberto De Vitto
Humberto De Vitto
YGYang Gang
Yang Gang
TZTaiping Zhang
Taiping Zhang
FCFerdinando Chiaradonna
Ferdinando Chiaradonna
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death and the search for a resolutive therapy is still a challenge. Since KRAS is commonly mutated in PDAC and is one of the main drivers of PDAC progression, its inhibition should be a key strategy for treatment, especially considering the recent development of specific KRAS inhibitors. Nevertheless, the effects of KRAS inhibition can be increased through the co-inhibition of other nodes important for cancer development. One of them could be the hexosamine biosynthetic pathway (HBP), whose enhancement is considered fundamental for PDAC. Here, we demonstrate that PDAC cells expressing oncogenic KRAS, owing to an increase in the HBP flux, become strongly reliant on HBP for both proliferation and survival. In particular, upon treatment with two different compounds, 2-deoxyglucose and FR054, inhibiting both HBP and protein N-glycosylation, these cells undergo apoptosis significantly more than PDAC cells expressing wild-type KRAS. Importantly, we also show that the combined treatment between FR054 and the pan-RAS inhibitor BI-2852 has an additive negative effect on cell proliferation and survival by means of the suppression of both Akt activity and cyclin D1 expression. Thus, co-inhibition of HBP and oncogenic RAS may represent a novel therapy for PDAC patients.

3 May 2018 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
APAlice Paiotta
Alice Paiotta
Giuseppe D'OrazioGiuseppe D'Orazio
Giuseppe D'Orazio
RPRoberta Palorini
Roberta Palorini
FRFrancesca Ricciardiello
Francesca Ricciardiello
Luca ZoiaLuca Zoia
Luca Zoia
Barbara La FerlaBarbara La Ferla
Barbara La Ferla